Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYSET vs ACARBOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in individuals with impaired glucose tolerance
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Acarbose is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes. Approximately 35% of the dose is absorbed as metabolites, which are excreted via the kidneys. The parent drug is not significantly metabolized by hepatic enzymes.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Negligible to low protein binding; less than 1-2% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Volume of distribution is not well defined due to minimal systemic absorption; estimated to be less than 0.3 L/kg, reflecting limited distribution beyond the gastrointestinal lumen.
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
Oral: Systemic bioavailability is very low (approximately 0.5-2%) due to local action in the GI tract and minimal absorption. The drug acts locally in the intestine; systemic levels are negligible.
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No specific dose adjustment required for GFR ≥25 m L/min; contraindicated in GFR <25 m L/min (creatinine clearance <25 m L/min).
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
No specific dose adjustment for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh class C).
Not recommended for pediatric patients due to lack of safety and efficacy data.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
Initiate at the lowest dose (25 mg 3 times daily); titrate slowly based on tolerance and glycemic control, as elderly patients may have reduced renal function and higher risk of gastrointestinal adverse effects.
None
None
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Risk of hepatotoxicity: rare cases of severe hepatocellular injury, including fulminant hepatitis, reported, especially at higher doses (≥300 mg/day); monitor liver enzymes periodically.,Use with caution in patients with renal impairment (e GFR <25 m L/min/1.73 m²): insufficient data; avoid use.,May cause hypoglycemia when used in combination with sulfonylureas or insulin; treat hypoglycemia with oral glucose (dextrose) rather than sucrose (acarbose inhibits sucrose digestion).,Gastrointestinal adverse effects (flatulence, diarrhea, abdominal pain) are common due to undigested carbohydrate fermentation in the colon; may subside with continued use.,Acute porphyria: acarbose has been associated with acute attacks in susceptible patients.
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
Hypersensitivity to acarbose or any component of the formulation,Diabetic ketoacidosis,Cirrhosis or significant hepatic impairment,Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Renal impairment (e GFR <25 m L/min/1.73 m²)
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
Acarbose delays digestion of complex carbohydrates and sucrose. To reduce gastrointestinal side effects, avoid high-sucrose foods and drinks. Simple sugars like glucose and fructose can still be absorbed and used to treat hypoglycemia. Alcohol may increase the risk of hypoglycemia when combined with acarbose, especially if taken with other antidiabetic agents.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposure. Risk cannot be excluded in first trimester. Second and third trimester: no known fetal risks, but use only if clearly needed.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
Acarbose is excreted into breast milk in negligible amounts due to low oral bioavailability and high molecular weight. M/P ratio not established. Considered compatible with breastfeeding; monitor infant for gastrointestinal effects (e.g., flatulence, diarrhea).
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to minimal systemic absorption. Initiate at 25 mg three times daily with meals; titrate based on 1-hour postprandial glucose levels.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Acarbose delays carbohydrate absorption by inhibiting alpha-glucosidase in the brush border of the small intestine. It should be taken with the first bite of each main meal. Its efficacy is limited by gastrointestinal side effects (flatulence, diarrhea) due to undigested carbohydrates reaching the colon. Not recommended in patients with inflammatory bowel disease or colonic obstruction. Hypoglycemia from acarbose (rare in monotherapy) must be treated with oral glucose or milk, not sucrose or complex carbohydrates, since their digestion is blocked. Acarbose can cause isolated transaminase elevations; monitor LFTs if symptoms occur.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
Take acarbose with the first bite of each main meal; do not take it between meals.,Common side effects include gas, bloating, and diarrhea, which may improve over time.,If you experience low blood sugar, treat it with glucose tablets, juice, or regular soda, not candy or fruit juice (acarbose blocks their digestion).,Tell your doctor if you develop jaundice or abdominal pain, as liver problems can occur.,This medication is not for weight loss and does not affect insulin secretion.
No interactions on record
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the gut, leading to a reduction in postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity in some patients, potentially increasing the risk of hypoglycemia when combined with acarbose. The interaction is primarily due to additive effects on glucose metabolism, and patients should be monitored for signs of hypoglycemia, particularly during initiation or dose adjustments."
"Chlorothiazide, a thiazide diuretic, can decrease the therapeutic efficacy of acarbose, an alpha-glucosidase inhibitor used for postprandial glycemic control in type 2 diabetes. The hypokalemia induced by chlorothiazide may impair insulin secretion and reduce the glucose-lowering effect of acarbose, potentially leading to elevated postprandial glucose levels. This interaction may necessitate dose adjustments or alternative antihyperglycemic therapy to maintain glycemic control."
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, thereby reducing postprandial hyperglycemia. Selegiline, a selective MAO-B inhibitor at therapeutic doses, can potentiate the hypoglycemic effect of acarbose by an unknown pharmacodynamic mechanism, potentially leading to episodes of hypoglycemia. This interaction is of particular concern in patients with diabetes mellitus who are co-prescribed these agents, as the combined effect on glucose homeostasis may require dose adjustments or enhanced monitoring."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYSET vs ACARBOSE, answered by our medical review team.
GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. ACARBOSE is a Alpha-Glucosidase Inhibitor that works by Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYSET and ACARBOSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. The standard adult dose of ACARBOSE is: Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYSET and ACARBOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. ACARBOSE is classified as Category C. Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.